The Advance-HTN trial in contrast remedy with the aldosterone synthase inhibitor lorundrostat vs. placebo for blood stress discount amongst adults with treatment-resistant hypertension.
Learn Healio’s in-depth protection of the Advance-HTN trial, together with skilled perspective.
The randomized, double-blind, placebo-controlled trial enrolled 285 sufferers with treatment-resistant hypertension, which was outlined as an automated systolic BP of 140 to 180 mm Hg whereas taking two to 5 BP drugs.
At 12 weeks, imply lower in 24-hour common systolic BP was 15.4 mm Hg for sufferers assigned 50 mg lorundrostat (Mineralys Therapeutics), 13.9 mm Hg for sufferers who escalated from 50 to 100 mg and seven.4 mm Hg for these assigned placebo.
Researchers reported a better incidence of hyperkalemia within the two lorundrostat teams.
The Advance-HTN trial was offered on the American Faculty of Cardiology Scientific Session and printed in The New England Journal of Medication.
Learn Healio’s full protection of ACC 2025 right here.
